RGX-314: Clinical Trials

4 trials of RGX-314, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 active not recruiting, 1 enrolling by invitation. 4 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 24Completed 2, Active not recruiting 1, Enrolling by invitation 1
Phase 11Completed 1
Phase 31Active not recruiting 1

Follow RGX-314: new trials by email Literature Review of RGX-314 trials Research Report on RGX-314

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)
RGX-314 - Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Phase 2CompletedAbbVie602021-02-222024-09-05
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
ABBV-RGX-314, Ranibizumab (LUCENTIS®) - AMD, nAMD
Phase 2 / Phase 3Active not recruitingAbbVie6712020-12-292026-04-28
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
RGX-314 - Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Phase 2Enrolling by invitationAbbVie8652019-05-312024-06-17
Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial
RGX-314 - Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration
Phase 1 / Phase 2CompletedREGENXBIO Inc.422017-03-292023-05-16

Conditions studied

Wet Macular Degeneration (3)  ·  Choroidal Neovascularization (1)  ·  Eye Diseases (1)  ·  Macular Degeneration (1)  ·  Retinal Degeneration (1)  ·  Retinal Diseases (1)

Sponsors

AbbVie (3)  ·  REGENXBIO Inc. (1)

Countries

United States (4)

Top investigators

Jeffrey Heier, MD (1)

Results publications

PMID 38554726